On May 13, 2026, Edesa Biotech, Inc. adjusted CEO Pardeep Nijhawan's compensation, with 90% of his salary paid in fully vested restricted share units instead of cash. Previously, he received 50% of his salary as RSUs, now altered as per the Amended Employment Agreement.